Biotechnology and Health Sciences Biotechnology and Health Sciences Biotech Health Sci http://www.Biotech-health.com 2383-0271 2383-028X 10.5812/bhs en jalali 2017 6 23 gregorian 2017 6 23 S 1
en 10.5812/bhs-41877 Investigation of Effective Factors on the Quality of Life of Patients Suffering from Ulcerative Colitis in Remission Investigation of Effective Factors on the Quality of Life of Patients Suffering from Ulcerative Colitis in Remission research-article research-article Objectives

In this study, we evaluated the quality of life (QOL) of these patients in the remission period of this disease.

Methods

Health-related quality of life (HRQOL) in 96 patients suffering from UC in clinical remission phase were evaluated by the use of two questionnaires of IBDQ and SF-36 which evaluate the domains of QOL and physical-psychological health, respectively. Results were analyzed by independent sample t-test and regression analysis using of SPSS version 22.

Conclusions

In patients suffering from UC in the remission phase males had a better HRQOL compared to females. Also remission period and absence of EIM have a positive effect on the QOL of these patients.

Results

Mean total scores from SF-36 and IBDQ tests were 79.5 ± 17.7 and 48.8 ± 9.5, respectively. Based on the results of IBD-Q test, the least score was given to the systemic symptoms (11.01 ± 3.17) and the most was related to the emotional function (30.06 ± 8.03). In the domain of physical-psychological health, physical health (15.06 ± 25.7) compared to the psychological health (33.5 ± 7.8) had a higher score. In addition, the mean total score from the IBD-Q test (P = 0.017), intestinal symptoms (P = 0.015) and emotional function (P = 0.007) were statistically more significant in males compared to the females.

Background

Ulcerative colitis (UC) is a chronic inflammatory disease with a variable and unpredictable course. This disease has noticeable consequences and by causing limitations in the life style of patients affects their quality of life.

Objectives

In this study, we evaluated the quality of life (QOL) of these patients in the remission period of this disease.

Methods

Health-related quality of life (HRQOL) in 96 patients suffering from UC in clinical remission phase were evaluated by the use of two questionnaires of IBDQ and SF-36 which evaluate the domains of QOL and physical-psychological health, respectively. Results were analyzed by independent sample t-test and regression analysis using of SPSS version 22.

Conclusions

In patients suffering from UC in the remission phase males had a better HRQOL compared to females. Also remission period and absence of EIM have a positive effect on the QOL of these patients.

Results

Mean total scores from SF-36 and IBDQ tests were 79.5 ± 17.7 and 48.8 ± 9.5, respectively. Based on the results of IBD-Q test, the least score was given to the systemic symptoms (11.01 ± 3.17) and the most was related to the emotional function (30.06 ± 8.03). In the domain of physical-psychological health, physical health (15.06 ± 25.7) compared to the psychological health (33.5 ± 7.8) had a higher score. In addition, the mean total score from the IBD-Q test (P = 0.017), intestinal symptoms (P = 0.015) and emotional function (P = 0.007) were statistically more significant in males compared to the females.

Background

Ulcerative colitis (UC) is a chronic inflammatory disease with a variable and unpredictable course. This disease has noticeable consequences and by causing limitations in the life style of patients affects their quality of life.

Ulcerative Colitis;Health Related Quality of Life;IBDQ;SF-36 Ulcerative Colitis;Health Related Quality of Life;IBDQ;SF-36 http://www.Biotech-health.com/index.php?page=article&article_id=41877 Ali Akbar Hajaghamohammadi Ali Akbar Hajaghamohammadi Department of Internal Medicine,Velayat Clinical Research Development Unit,Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran Department of Internal Medicine,Velayat Clinical Research Development Unit,Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran Bahareh Keshavarzi Bahareh Keshavarzi Velayat Clinical Research Development Unit, Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran Velayat Clinical Research Development Unit, Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran Ali Zargar Ali Zargar Department of Internal Medicine,Velayat Clinical Research Development Unit,Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran; Department of Internal Medicine,Velayat Clinical Research Development Unit,Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran. Tel: +98-2833760620 Department of Internal Medicine,Velayat Clinical Research Development Unit,Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran; Department of Internal Medicine,Velayat Clinical Research Development Unit,Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran. Tel: +98-2833760620